NAVBQ (Navidea Biopharmaceuticals) Cyclically Adjusted PS Ratio: (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAVBQ Navidea Biopharmaceuticals Inc NAVBQ
16 GF Score
Price $0.00
View Full Analysis

What is Navidea Biopharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Navidea Biopharmaceuticals  (OTCPK:NAVBQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Navidea Biopharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Navidea Biopharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Navidea Biopharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals Cyclically Adjusted PS Ratio Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 0.00 8.61 0.00 0.00

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NAVBQ vs PKBO, RSPI, ATRX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Cyclically Adjusted PS Ratio falls into.


NAVBQ
16GF Score
Navidea Biopharmaceuticals Inc NAVBQ
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navidea Biopharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Navidea Biopharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Navidea Biopharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/307.7890*307.7890
=0.000

Current CPI (Sep. 2023) = 307.7890.

Navidea Biopharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.080 233.049 0.106
201403 0.104 236.293 0.135
201406 0.143 238.343 0.185
201409 0.300 238.031 0.388
201412 0.293 234.812 0.384
201503 0.281 236.119 0.366
201506 0.382 238.638 0.493
201509 0.530 237.945 0.686
201512 -1.009 236.525 -1.313
201603 0.122 238.132 0.158
201606 0.150 241.018 0.192
201609 0.235 241.428 0.300
201612 -0.271 241.432 -0.345
201703 0.000 243.801 0.000
201706 0.012 244.955 0.015
201709 0.000 246.819 0.000
201712 0.001 246.524 0.001
201803 0.000 249.554 0.000
201806 0.032 251.989 0.039
201809 0.003 252.439 0.004
201812 0.004 251.233 0.005
201903 0.000 254.202 0.000
201906 0.001 256.143 0.001
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.001 258.115 0.001
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 0.003 260.474 0.004
202103 0.001 264.877 0.001
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Navidea Biopharmaceuticals Business Description

Address 4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score

Get the complete analysis for NAVBQ

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price